Ephrin-A1 promotes the malignant progression of intestinal tumors in Apcmin/+ mice

被引:18
作者
Shi, L. [1 ]
Itoh, F. [1 ]
Itoh, S. [1 ]
Takahashi, S. [2 ,3 ]
Yamamoto, M. [4 ,5 ]
Kato, M. [1 ]
机构
[1] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Expt Pathol, Tsukuba, Ibaraki 3058575, Japan
[2] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Anat, Tsukuba, Ibaraki 3058575, Japan
[3] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Embryol, Tsukuba, Ibaraki 3058575, Japan
[4] Tohoku Univ, Grad Sch Med, Dept Med Biochem, Sendai, Miyagi 980, Japan
[5] Japan Sci & Technol Corp, ERATO Environm Response Project, Tsukuba, Ibaraki, Japan
关键词
ephrin-A1; intestinal adenoma; invasion Apc(min/+) mice;
D O I
10.1038/sj.onc.1210992
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ephrin-A1 and EphA receptors are frequently highly expressed in different human cancers, suggesting that they may promote tumor development and progression. We generated transgenic mice carrying Fabpl(4xat-132) ephrin-A1, which express ephrin-A1 in the intestinal epithelial cells. Those mice were then mated with Apc(min/+) mice to produce the compound mice, which overexpress ephrin-A1 in the intestinal tumors of Apc(min/+) mice. We compared the number, size and histopathological features of the intestinal tumors in the Fabpl(4xat-132) ephrin-A1/Apc(min/+) compound mice with those of the Apc(min/+) mice. The compound mice showed an increased number of intestinal tumors, significantly in the large intestine, and developed more invasive tumors. Among the 20 mice of each type examined, 5 Apc(min/+) mice developed 5 invasive tumors, 1 invasive tumor in each mouse, in the proximal or middle portions of the small intestine. On the other hand, 14 out of 20 compound mice developed 29 invasive tumors and 16 of them were in the distal small intestine and the large intestine, where transgenic ephrin-A1 was highly expressed. These results suggested that the increased expression of ephrin-A1 accelerated the malignant progression of the intestinal adenoma to invasive tumors.
引用
收藏
页码:3265 / 3273
页数:9
相关论文
共 37 条
[1]   Expression of EphA2 and ephrin A-1 in carcinoma of the urinary bladder [J].
Abraham, S ;
Knapp, DW ;
Cheng, L ;
Snyder, PW ;
Mittal, SK ;
Bangari, DS ;
Kinch, M ;
Wu, L ;
Dhariwal, J ;
Mohammed, SI .
CLINICAL CANCER RESEARCH, 2006, 12 (02) :353-360
[2]   EphB receptor activity suppresses colorectal cancer progression [J].
Batlle, E ;
Bacani, J ;
Begthel, H ;
Jonkeer, S ;
Gregorieff, A ;
van de Born, M ;
Malats, N ;
Sancho, E ;
Boon, E ;
Pawson, T ;
Gallinger, S ;
Pals, S ;
Clevers, H .
NATURE, 2005, 435 (7045) :1126-1130
[3]   Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice [J].
Brantley-Sieders, Dana M. ;
Fang, Wei Bin ;
Hwang, Yoonha ;
Hicks, Donna ;
Chen, Jin .
CANCER RESEARCH, 2006, 66 (21) :10315-10324
[4]   Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression [J].
Brantley-Sieders, DM ;
Fang, WB ;
Hicks, DJ ;
Zhuang, GL ;
Yu, S ;
Chen, J .
FASEB JOURNAL, 2005, 19 (11) :1884-+
[5]  
Coffman KT, 2003, CANCER RES, V63, P7907
[6]   ENDOCRINE-CELLS IN COLORECTAL ADENOCARCINOMAS - INCIDENCE, HORMONE PROFILE AND PROGNOSTIC RELEVANCE [J].
DEBRUINE, AP ;
WIGGERS, T ;
BEEK, C ;
VOLOVICS, A ;
VONMEYENFELDT, M ;
ARENDS, JW ;
BOSMAN, FT .
INTERNATIONAL JOURNAL OF CANCER, 1993, 54 (05) :765-771
[7]   Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist [J].
Dobrzanski, P ;
Hunter, K ;
Jones-Bolin, S ;
Chang, H ;
Robinson, C ;
Pritchard, S ;
Zhao, H ;
Ruggeri, B .
CANCER RESEARCH, 2004, 64 (03) :910-919
[8]  
Flanagan JG, 1997, CELL, V90, P403
[9]  
Hamamoto T, 2002, CANCER RES, V62, P5955
[10]   Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival [J].
Herath, Nirmitha I. ;
Spanevello, Mark D. ;
Sabesan, Sabe ;
Newton, Tanya ;
Cummings, Margaret ;
Duffy, Shannon ;
Lincoln, Douglas ;
Boyle, Glen ;
Parsons, Peter G. ;
Boyd, Andrew W. .
BMC CANCER, 2006, 6 (1)